Table 1—

Pain visual analogue scale (UCS, UCES, and pooled cohorts)

PlaceboALC 500 mg t.i.d.ALC 1,000 mg t.i.d.ANOVA P value (placebo vs. 500 mg ALC)ANOVA P value (placebo vs. 1,000 mg ALC)
UCS
    n486170
    Baseline50.40 ± 21.8857.80 ± 25.9259.94 ± 24.12NSNS
    Week 26 change−10.25 ± 29.45−17.59 ± 32.53−23.26 ± 26.33NS0.021
    Week 52 change−9.72 ± 31.12−13.16 ± 32.64−25.53 ± 28.75NS0.024*
UCES
    n614358
    Baseline53.21 ± 25.9648.28 ± 23.3056.89 ± 26.94NSNS
    Week 26 change−18.93 ± 26.20−14.21 ± 26.82−21.92 ± 31.28NSNS
    Week 52 change−14.51 ± 27.49−11.84 ± 30.80−21.75 ± 34.58NSNS
Pooled cohorts
    n109104128
    Baseline51.98 ± 24.1853.86 ± 25.2058.56 ± 25.38NSNS
    Week 26 change−15.11 ± 27.89−16.19 ± 30.21−22.89 ± 28.57NS0.031
    Week 52 change−12.40 ± 29.11−12.61 ± 31.74−23.82 ± 31.45NS0.025
  • Data are means ± SD for the change over baseline in intention-to-treat patients.

  • *

    * Repeated-measures ANOVA overall P value = 0.031.

  • Repeated-measures ANOVA overall P value = 0.017.